Simpson Thacher recently represented Sumitomo Pharma Co., Ltd. in connection with its ¥113 billion (approximately US$711 million) global offering of 51,304,400 newly issued shares with the over-allotment option, including an international offering to institutional investors outside Japan pursuant to Rule 144A, and to institutional investors outside Japan and the United States pursuant to Regulation S.
Sumitomo Pharma Co., Ltd. is an R&D-driven pharmaceutical company that discovers, develops, manufactures and commercializes prescription pharmaceuticals, including drugs and biologics such as regenerative medicine/cell therapy programs that generates a material portion of its revenue in the United States and Japan.
The international lead managers for the international offering were SMBC Bank International plc, Daiwa Capital Markets Europe Limited, Nomura International plc and Mizuho International plc.
The Simpson Thacher team included Taki Saito, Weiwei Chen and Yoshimi Koshiishi (Capital Markets); Vanessa Burrows, Jacob Madden and Alison Peters (Regulatory Matters); Michael Mann (Tax); and George Gerstein (Executive Compensation and Employee Benefits).